Therapist training trial on how experience shapes therapy
Part of Mental health clinical trials.
This study looks at how therapists’ personal experience affects their attitude and skills during substance-assisted therapy training. It’s mainly for therapists-in-training, and may help improve how future training and therapy are delivered safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are enrolled in the SÄPT therapist training (medical doctors or psychologists)
- You are 27 years or older and can understand German well enough for the study
- You understand the study steps and risks, and agree to follow the protocol and sign consent
- After the study substance is given, you will not drive or operate heavy machinery for 24 hours
- You have no history of a major bad reaction to hallucinogenic drugs
- You have no serious medical or major mental health conditions that would make participation unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares how three different psychedelic substances affect your state of mind. The goal is to better understand these altered states, which may help develop future treatments.
This trial tests psilocybin (a compound from certain mushrooms) combined with a structured therapy to see if it helps people with depression linked to trauma. It focuses on how the treatment affects the connection between the gut and brain.
This trial tests if psilocybin, a substance found in certain mushrooms, can help people with various mental health symptoms that affect daily life. You would take a single dose in a supervised setting and be monitored for changes in your mood and well-being.
This trial tests if MDMA-assisted therapy can help mental healthcare providers. It involves taking MDMA in a therapeutic setting while being recorded, and you must be trained in this type of therapy.
This trial tests how the setting and context affect the experience of psilocybin, a psychedelic drug. It aims to understand how the environment influences the effects in healthy adults.
This study tests a group therapy program that includes a psychedelic medicine for first responders struggling with conditions like depression, anxiety, or PTSD. It is a 12-week program with mostly remote sessions and two in-person visits.
Hear when a new Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.